Comparing the current results to its competitors, Harrow Inc reported Revenue increase in the 2 quarter 2026 by 11.26 % year on year. The revenue growth was below Harrow Inc 's competitors' average revenue growth of 11.42 %, achieved in the same quarter.
Harrow Inc 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical industry, competing with branded and generic pharmaceutical companies, biosimilar manufacturers, and other firms developing or commercializing ophthalmic therapies for ocular surface disease, perioperative care, and retina. Competitors often possess greater financial, technical, manufacturing, and commercial resources, including larger sales forces, broader distribution networks, and increased access to capital. These advantages may enable competitors to develop, obtain regulatory approval for, manufacture, market, and sell products more effectively. The company may face challenges in gaining or maintaining market share, achieving favorable formulary placement and reimbursement, securing manufacturing capacity and supply chain reliability, and sustaining pricing and margins. The industry experiences rapid technological change, requiring companies to maintain competitive positions regarding new therapies, delivery methods, and competitive entrants such as generics and biosimilars. Competitors may introduce products that are safer, more effective, easier to use, more durable, more convenient, more cost-effective, or that achieve greater market access through reimbursement or contracting advantages, which could reduce demand for the company's existing products and impact the commercial viability of its product candidates or lifecycle management initiatives.
Overall company revenue, increased less, than total company revenues, at 11.26 % and lost market share, to approximately 0.33 %. << More on HROW Market Share.
*Market share is calculated based on total revenue.
July 12, 2024
In a recent announcement, Harrow, a prominent North American eyecare pharmaceutical company, disclosed its plan to attend the highly anticipated 2024 American Society of Retina Specialists (ASRS) Annual Meeting. The event is scheduled to take place in Stockholm, Sweden, from July 17th to 20th, 2024. This strategic move reflects Harrow s commitment to global expansion and demonstrates their desire to collaborate with industry leaders and experts in the field of retinal health and treatment.The ASRS Annual Meeting serves as a notable gathering for the world s leading retina specialists, diligent researchers, and influential industry figures. This congregation facilitates an exchange of knowledge, discoveries, ...
July 9, 2024
Harrow Joins Apexus 340B Prime Vendor Program to Expand Access to IHEEZO and Other Essential Eyecare ProductsNASHVILLE, Tenn. - Harrow, a prominent eyecare pharmaceutical company in North America, has officially partnered with Apexus, a leading organization in the healthcare industry, to include their innovative product, IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3%, in the renowned 340B Prime Vendor Program. This collaboration aims to provide broader access to IHEEZO and other key Harrow products, effective July 1, 2024.IHEEZO, specially formulated for ocular anesthesia, offers a low-viscosity topical ocular anesthetic gel that ensures reliable efficacy while maintaining a proven safety profile. ...
June 5, 2024
Harrow, a renowned North American eyecare pharmaceutical company, has recently unveiled encouraging results from their ESSENCE2 open-label extension (OLE) clinical study for VEVYE (cyclosporine ophthalmic solution) 0.1%. This is the first and only medication of its kind designed to address the signs and symptoms of dry eye disease (DED). Conducted as a Phase 3, prospective, multicenter trial, the ESSENCE-2 OLE study involved 202 patients who had previously completed the ESSENCE2 study.Study Details and Implications:Utilizing an open-label design, the ESSENCE-2 OLE clinical study assessed the long-term efficacy and safety of VEVYE in treating DED. Patients who previously participated in the ESSENCE2 study, ev...
May 15, 2024
Harrow to Present at Two Investor Conferences in MayNASHVILLE, Tenn. - Harrow (Nasdaq: HROW), a prominent eyecare pharmaceutical company in North America, recently made an exciting announcement regarding its participation in two investor conferences in May. With a focus on strengthening investor relations and showcasing their growth prospects, Harrow s management will engage in informative sessions and discussions with industry professionals.The first conference on the agenda is the B. Riley Securities 24th Annual Institutional Investor Conference, set to take place at the prestigious Beverly Hilton Hotel in Beverly Hills, CA. Harrow s management will participate in a Fireside Chat format, offering attendees...
May 13, 2024
In a recent announcement, Harrow, a renowned eyecare pharmaceutical company in North America, disclosed its financial results for the first quarter ended on March 31, 2024. This disclosure included the publication of the Company s first quarter Letter to Stockholders and corporate presentation on their official website, harrow.com. Harrow emphasizes the significance of these documents for all its stockholders, as they offer further insights into the historical performance during this quarter and outline future expectations.The financial report presented by Harrow underscores the success achieved by the company during the initial quarter of 2024. As a leading eyecare pharmaceutical company, Harrow has firmly ...
Ocular Therapeutix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for diseases and conditions of the eye. They utilize their proprietary hydrogel technology to design and manufacture sustained-release treatments that can be administered during routine eye exams and eliminate the need for patient compliance with eye drops.
Oculis Holding Ag is a pharmaceutical company that specializes in developing and commercializing innovative ophthalmic treatments. Their business model revolves around conducting in-depth research and development to formulate eye medications that target various ocular diseases. They then seek regulatory approvals and form strategic partnerships to manufacture and distribute their products globally, aiming to improve eye health and provide effective treatment options for patients.
Kiora Pharmaceuticals Inc operates with a business model focused on the research, development, and commercialization of innovative pharmaceutical products for various medical conditions and diseases. The company aims to create value through the discovery of new drugs, rigorous clinical trials, and strategic partnerships for ultimate patient benefit and sustainable growth.
Kala Pharmaceuticals Inc operates on a business model that revolves around the development and commercialization of innovative ophthalmic therapeutics to address unmet needs in eye care. Their approach focuses on utilizing their proprietary mucus-penetrating particle (MPP) technology to enhance drug delivery and improve patient outcomes. By leveraging partnerships and collaborations with industry stakeholders, Kala Pharmaceuticals aims to bring novel therapies to market and improve the standard of care for various eye diseases.
Eyepoint Pharmaceuticals Inc is a pharmaceutical company that operates on a specialty business model focused on advancing ophthalmic therapies. They develop and commercialize innovative treatments using their proprietary drug delivery technology, allowing for sustained release of drugs to the eye. By leveraging their expertise in ophthalmology and controlled release technology, Eyepoint aims to improve patient outcomes and address unmet medical needs in eye care.
Sources:
Harrow Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Harrow Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
